Review
Medicine, General & Internal
Carla J. Gargallo-Puyuelo, Viviana Laredo, Fernando Gomollon
Summary: Thiopurines play a crucial role in the treatment of IBD, but there are still unresolved issues regarding their efficacy and safety. Personalized therapy based on pharmacogenomics and genetic polymorphisms of metabolizing enzymes may help prevent side effects. Factors such as age, ethnicity, and viral infections also influence the outcomes of thiopurine therapy.
FRONTIERS IN MEDICINE
(2021)
Letter
Gastroenterology & Hepatology
Flora Maria Lorenzo Fortes, Raquel Rocha, Genoile Oliveira Santana
Summary: The use of thiopurines increases the risk of active tuberculosis in patients with inflammatory bowel disease.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Doriane Broussard, Pauline Riviere, Joelle Bonnet, Ginette Fotsing, Aurelien Amiot, Laurent Peyrin-Biroulet, Sylvie Rajca, Anthony Buisson, Cyrielle Gilleta, Anne-Laure Pelletier, Melanie Serrero, Guillaume Bouguen, Romain Altwegg, Xavier Hebuterne, Stephane Nancey, Mathurin Fumery, Guillaume Cadiot, Stephane Nahon, Jean-Francois Rahier, Jean-Marc Gornet, Veronique Vendrely, David Laharie
Summary: A retrospective multicentre study was conducted to assess the impact of abdominal or pelvic radiotherapy on IBD course. Most patients with non-active IBD can be safely treated with radiotherapy, but patients with acute gut toxicity and without concomitant chemotherapy should be more closely monitored post-radiotherapy.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Pharmacology & Pharmacy
Keiichi Tominaga, Takeshi Sugaya, Takanao Tanaka, Mimari Kanazawa, Makoto Iijima, Atsushi Irisawa
Summary: Thiopurines are medications used to treat inflammatory bowel diseases, particularly ulcerative colitis, with the potential to alleviate symptoms and maintain long-term remission. Careful monitoring is needed for adverse events associated with long-term use, while these drugs also play a critical role in controlling immunogenicity and predicting serious adverse events. However, the consequences of thiopurine withdrawal remain uncertain and further research is required to address this clinical question.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Katarzyna Dziabowska-Grabias, Malgorzata Sztanke, Przemyslaw Zajac, Michal Celejewski, Katarzyna Kurek, Stanislaw Szkutnicki, Patryk Korga, Wlodzimierz Bulikowski, Krzysztof Sztanke
Summary: Inflammatory bowel diseases (IBD) are chronic, incurable diseases of the digestive tract with unclear etiology, resulting in significant impact on patients' quality of life. The incidence and prevalence of IBD are continuously increasing worldwide, becoming a significant public health burden. Current pharmaceutical management options often have side effects and may not provide sufficient disease control, leading to research on antioxidant and anti-inflammatory substances as potential treatment options.
Article
Gastroenterology & Hepatology
Paula Sousa, Paula Ministro, Alessandro Armuzzi, Axel Dignass, Marte Lie Hoivik, Manuel Barreiro-de Acosta, Stephan Vavricka, Rogerio Saad-Hossne, Paulo Gustavo Kotze, Laurent Peyrin-Biroulet, Fernando Magro
Summary: Majority of surveyed IBD physicians use thiopurines for treating CD and UC, considering them to have good safety profile. Despite emerging treatments, most physicians believe that thiopurines will remain an important part of the treatment algorithm for CD and UC.
DIGESTIVE AND LIVER DISEASE
(2021)
Article
Gastroenterology & Hepatology
Uma Mahadevan, Millie D. Long, Sunanda Kane, Abhik Roy, Marla C. Dubinsky, Bruce E. Sands, Russell D. Cohen, Christina D. Chambers, William J. Sandborn
Summary: The study found that exposure to biologic, thiopurine, or combination therapy during pregnancy did not increase adverse maternal or fetal outcomes, and these treatments can be continued throughout pregnancy for women with IBD to maintain disease control.
Article
Gastroenterology & Hepatology
Mukesh Kumar Ranjan, Sudheer Kumar Vuyyuru, Bhaskar Kante, Peeyush Kumar, Sandeep K. Mundhra, Rithvik Golla, Raju Sharma, Peush Sahni, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet Ahuja
Summary: Approximately 50% of patients with IBD in remission would relapse after 5 years of thiopurine withdrawal. Male sex and shorter treatment duration predict relapse.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2022)
Review
Biochemistry & Molecular Biology
HyunTaek Jung, Jae Seok Kim, Keum Hwa Lee, Kalthoum Tizaoui, Salvatore Terrazzino, Sarah Cargnin, Lee Smith, Ai Koyanagi, Louis Jacob, Han Li, Sung Hwi Hong, Dong Keon Yon, Seung Won Lee, Min Seo Kim, Paul Wasuwanich, Wikrom Karnsakul, Jae Il Shin, Andreas Kronbichler
Summary: Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract that mainly affects young people. Recent studies have shown that microRNAs (miRNAs) play an important role in the pathogenesis, diagnosis, and treatment of IBD.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Antoine Meyer, Marion Taine, Jerome Drouin, Alain Weill, Franck Carbonnel, Rosemary Dray-Spira
Summary: This study compared the risk of serious infections in children with in utero exposure to thiopurines and/or anti-TNF born to mothers with inflammatory bowel disease (IBD). The results showed that in the first 5 years of life, children exposed to thiopurine monotherapy and anti-TNF monotherapy had similar risks of serious infections compared to unexposed children, while children exposed to combination therapy had a higher risk.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Nutrition & Dietetics
Jose M. Comeche, Ana Gutierrez-Hervas, Jose Tuells, Cesare Altavilla, Pablo Caballero
Summary: Predefined diets have shown partial efficacy in treating inflammatory bowel disease, although doubts exist regarding specific indicators. Further research is needed to evaluate the influence of predefined diets on IBD patients.
Article
Geriatrics & Gerontology
Margalida Calafat, Miriam Manosa, Fiorella Canete, Eugeni Domenech
Summary: With the increasing number of older patients with inflammatory bowel disease (IBD), disease management in this population is challenged by comorbidities and polypharmacy. Thiopurines still play a significant role in the treatment of IBD in older patients, but adverse events should be carefully monitored.
Review
Immunology
Zhengping Che, Ziyu Ye, Xueying Zhang, Bihua Lin, Weiqing Yang, Yanfang Liang, Jincheng Zeng
Summary: Inflammatory bowel diseases (IBDs) are a group of chronic inflammatory disorders of the gastrointestinal tract. Current treatments are not fully curative and often lead to relapse. Mesenchymal stem/stromal cells (MSCs), with their multipotent differentiation and immunomodulatory capabilities, show potential for the treatment of IBDs.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Gastroenterology & Hepatology
Shannon Linda Kanis, Sanne Modderman, Johanna C. Escher, Nicole Erler, Ruud Beukers, Nanne de Boer, Alexander Bodelier, Annekatrien C. T. M. Depla, Gerard Dijkstra, Anne-Baue Ruth Margaretha van Dijk, Lennard Gilissen, Frank Hoentjen, Jeroen M. Jansen, Johan Kuyvenhoven, Nofel Mahmmod, Rosalie C. Mallant-Hent, Andrea E. Van der Meulen-de Jong, Anahita Noruzi, Bas Oldenburg, Liekele E. Oostenbrug, Pieter C. J. Ter Borg, Marieke Pierik, Marielle Romberg-Camps, Willem Thijs, Rachel West, Alison de Lima, C. Janneke van der Woude
Summary: This study aimed to describe the long-term health outcomes of children born to mothers with inflammatory bowel disease (IBD) and assess the impact of maternal IBD medication use on these outcomes. The results showed no association between in utero exposure to anti-TNF-alpha and/or thiopurine and long-term health outcomes, but an increased rate of intrahepatic cholestasis of pregnancy (ICP) was found when thiopurine was used during pregnancy.
Article
Immunology
Michele Aramburu Serafini, Dienifer Hermann Sirena, Ana Beatriz Tittoni da Silveira, Monique Franco-da-Silva, Mariana Rauback Aubin, Tuane Nerissa Alves Garcez, Anelise Araujo, Fernanda dos Santos Pereira, Martin J. Hoogduijn, Fabiany da Costa Goncalves, Ana Helena Paz
Summary: Inflammatory bowel diseases (IBD), including ulcerative colitis, are chronic inflammations of the gastrointestinal tract. Mesenchymal stromal cells (MSC) have shown promise as a therapy for IBD, but practical complexities arise from using living cells. This study investigated the potential of MSC-derived membrane particles (MP) and conditioned media (CM) as cell-free therapies for IBD, and found that they ameliorated colitis symptoms in a mouse model.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Gastroenterology & Hepatology
Alessandro Vitello, Mauro Grova, Daniela Pugliese, Fernando Rizzello, Francesco Lanzarotto, Alessandro Lavagna, Roberta Caccaro, Maria Cappello, Anna Viola, Davide Giuseppe Ribaldone, Mariabeatrice Principi, Elisa Stasi, Maria Lia Scribano, Marcello Maida, Alessandra Soriano, Cristina Bezzio, Giorgia Bodini, Filippo Mocciaro, Antonio Carlo Privitera, Daniele Simondi, Enrica Giuffrida, Renata D'Inca, Chiara Ricci, Paolo Gionchetti, Alessandro Armuzzi, Ambrogio Orlando, Marco Daperno
Summary: Adalimumab is safe and effective for the treatment of ulcerative colitis, with a certain proportion of patients requiring colectomy during long-term treatment.
DIGESTIVE AND LIVER DISEASE
(2022)
Review
Gastroenterology & Hepatology
Alessandro Armuzzi, Aurora Bortoli, Fabiana Castiglione, Antonella Contaldo, Marco Daperno, Renata D'Inca, Nunzia Labarile, Silvia Mazzuoli, Sara Onali, Monica Milla, Ambrogio Orlando, Mariabeatrice Principi, Daniela Pugliese, Sara Renna, Fernando Rizzello, Maria Lia Scribano, Alessia Todeschini
Summary: Inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease, have a significant impact on the quality of life of patients worldwide. Women with these conditions face gender-specific issues related to body image, sexuality, menstruation, contraception, fertility, pregnancy, breastfeeding, and menopause. It is important for physicians specializing in inflammatory bowel diseases to recognize and address these concerns to ensure the overall well-being and health of female patients.
DIGESTIVE AND LIVER DISEASE
(2022)
Article
Gastroenterology & Hepatology
Carla Marinelli, Fabiana Zingone, Maria Giovanna Lupo, Raffaella Marin, Renata D'Inca, Alessandro Gubbiotti, Davide Massimi, Cesare Casadei, Brigida Barberio, Nicola Ferri, Edoardo Savarino
Summary: This study evaluated the levels of PCSK9 in patients with ulcerative colitis (UC) and their relationship with disease activity. The results showed that patients with abnormal fecal calprotectin and/or C-reactive protein had higher levels of PCSK9. There was a positive correlation between PCSK9 levels and endoscopic scores, fecal calprotectin, and UC-Riley Index. Additionally, PCSK9 levels were positively correlated with cholesterol values.
JOURNAL OF CLINICAL GASTROENTEROLOGY
(2022)
Article
Oncology
Benedetto Neri, Maria Lia Scribano, Alessandro Armuzzi, Fabiana Castiglione, Renata D'Inca, Ambrogio Orlando, Stefano Festa, Gabriele Riegler, Walter Fries, Gianmichele Meucci, Patrizia Alvisi, Filippo Mocciaro, Claudio Papi, Michelangela Mossa, Giorgia Sena, Luisa Guidi, Anna Testa, Sara Renna, Iris Frankovic, Anna Viola, Marta Patturelli, Carlo Chiaramonte, Livia Biancone
Summary: The sequence chronic inflammation-dysplasia-cancer is involved in the development of several gastrointestinal cancers. The characteristics of IBD, including CRC-related symptoms at onset, play a role in the long-term outcome of CRC in IBD patients. CRC has a higher incidence in UC and CD patients. Surveillance programs should focus on high-risk subgroups of patients.
Article
Gastroenterology & Hepatology
Maria Lia Scribano, Annalisa Aratari, Benedetto Neri, Cristina Bezzio, Paola Balestrieri, Valentina Baccolini, Giuliano Falasco, Caterina Camastra, Paolo Pantanella, Rita Monterubbianesi, Alessandro Tullio, Simone Saibeni, Claudio Papi, Livia Biancone, Rocco Cosintino, Roberto Faggiani
Summary: This study assessed the effectiveness of ustekinumab in a large cohort of Italian patients with refractory Crohn's disease. The results showed that ustekinumab can achieve corticosteroid-free clinical remission in most patients, with significant decreases in HBI and CRP values. The normalization rate of CRP values also increased over time.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2022)
Review
Gastroenterology & Hepatology
Dikshita Deka, Renata D'Inca, Giacomo Carlo Sturniolo, Alakesh Das, Surajit Pathak, Antara Banerjee
Summary: Endoplasmic reticulum stress, caused by cellular mechanism, may contribute to the pathogenesis of inflammatory bowel disease by disrupting protein synthesis, inducing epithelial cell apoptosis, and triggering inflammatory reactions in the gut. Pharmacological intervention to restore unfolded protein response balance in the endoplasmic reticulum could be a novel therapeutic approach for treating inflammatory bowel diseases.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Gaetano Bergamaschi, Fabiana Castiglione, Renata D'Inca, Marco Astegiano, Walter Fries, Monica Milla, Carolina Ciacci, Fernando Rizzello, Simone Saibeni, Rachele Ciccocioppo, Ambrogio Orlando, Fabrizio Bossa, Mariabeatrice Principi, Piero Vernia, Chiara Ricci, Maria L. Scribano, Giorgia Bodini, Dario Mazzucco, Gabrio Bassotti, Gabriele Riegler, Andrea Buda, Matteo Neri, Flavio Caprioli, Fabio Monica, Aldo Manca, Erica Villa, Gionata Fiorino, Michele Comberlato, Nicola Aronico, Cristina Della Corte, Roberta Caccaro, Paolo Gionchetti, Paolo Giuffrida, Paola Iovino, Marco Lenti, Caterina Mengoli, Lucienne Pellegrini, Alberto Pieraccini, Davide Ribaldone, Anna Testa, Cristina Ubezio, Anna Viola, Maurizio Vecchi, Catherine Klersy, Antonio Di Sabatino
Summary: The prevalence of anemia in Italian IBD patients is lower than previously reported, with the majority being caused by iron deficiency and leading to fatigue and decreased quality of life. However, a large proportion of patients with iron and/or vitamin deficiencies remain untreated.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Surgery
Imerio Angriman, Annaclaudia Colangelo, Claudia Mescoli, Matteo Fassan, Renata D'Inca, Edoardo Savarino, Salvatore Pucciarelli, Romeo Bardini, Cesare Ruffolo, Marco Scarpa
Summary: The study confirmed the accuracy of the Padua Prognostic Score for Colitis (PPSC) in predicting postoperative fistulas or abscesses and pouchitis. Therefore, in clinical practice, patients with a PPSC score greater than 1 should be warned of the risk of possible Crohn's disease diagnosis and pouch failure.
FRONTIERS IN SURGERY
(2022)
Article
Gastroenterology & Hepatology
Michael L. Schilsky, Anna Czlonkowska, Massimo Zuin, David Cassiman, Carlos Twardowschy, Aurelia Poujois, Francisco De Assis A. Gondim, Gerald Denk, Rubens G. Cury, Peter Ott, Joanna Moore, Aftab Ala, Renata D'Inca, Eduardo Couchonnal-Bedoya, Koenraad D'Hollander, Nicolas Dubois, C. Omar F. Kamlin, Karl Heinz Weiss
Summary: The study compares the effectiveness of penicillamine and TETA4 in maintenance therapy for Wilson disease. The results show that TETA4 is non-inferior to penicillamine and is well tolerated in adults with Wilson disease.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2022)
Review
Oncology
Cristina Bezzio, Marta Vernero, Davide Giuseppe Ribaldone, Eleonora Alimenti, Gianpiero Manes, Simone Saibeni
Summary: Tofacitinib is a novel therapy for immune-mediated inflammatory diseases, but safety concerns regarding cardiovascular side effects and cancer risk have been raised. This meta-analysis compared the cancer risk of tofacitinib with a placebo and other therapies and found no significant difference in overall cancer risk. However, a slightly higher risk of cancer was observed in patients treated with tofacitinib compared to those treated with tumor necrosis factor inhibitors. Further studies are needed to better understand the cancer risk of tofacitinib therapy.
Article
Medicine, General & Internal
Marta Vernero, Cristina Bezzio, Davide G. Ribaldone, Stefania Costa, Davide Scalvini, Elisa Tribocco, Gianpiero Manes, Simone Saibeni
Summary: This study evaluated the effectiveness and safety of GP2017, a biosimilar drug, in the treatment of inflammatory bowel disease (IBD). The results showed that GP2017 is an effective and safe therapy for IBD patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Meeting Abstract
Gastroenterology & Hepatology
B. Neri, M. L. Scribano, A. Armuzzi, F. Castiglione, R. D'Inca, A. Orlando, S. Festa, G. Riegler, W. Fries, G. Meucci, P. Alvisi, F. Mocciaro, C. Papi, M. Mossa, G. Sena, L. Guidi, A. Testa, S. Renna, I Frankovic, A. Viola, M. Patturelli, C. Chiaramonte, L. Biancone
DIGESTIVE AND LIVER DISEASE
(2022)
Meeting Abstract
Gastroenterology & Hepatology
C. Bezzio, A. D. Guarino, I. Arena, C. Della Corte, M. Devani, G. Manes, M. Schettino, E. Sablich, M. Vernero, S. Saibeni
JOURNAL OF CROHNS & COLITIS
(2022)
Meeting Abstract
Gastroenterology & Hepatology
C. Bezzio, S. Costa, A. Armuzzi, F. Furfaro, S. Ardizzone, M. Milla, F. Bossa, A. Orlando, F. A. Caprioli, F. Castiglione, C. Vigano, D. G. Ribaldone, F. Zingone, R. Monterubbianesi, N. Imperatore, S. Festa, M. Daperno, L. Scucchi, A. Ferronato, L. Pastorelli, P. Balestrieri, C. Ricci, M. Cappello, C. Felice, F. Coppini, P. Alvisi, V. Gerardi, A. Variola, S. Mazzuoli, M. V. Lenti, S. Alessandro, A. Buda, F. Micheli, V. Ciardo, G. Casella, A. Viscido, G. Bodini, G. Fiorino, M. Vernero, S. Saibeni
JOURNAL OF CROHNS & COLITIS
(2022)